Emmecell
Onkar Sawant, Ph.D., currently serves as a Board Observer at Emmecell since February 2024 and has held the position of Vice President of Research & Development at Eversight since June 2019, where responsibilities include directing research and innovation efforts. Previously, Onkar was a Visiting Scientist, Research Associate, and Postdoctoral Research Fellow at Cleveland Clinic from January 2014 to September 2019. Onkar's academic background includes a Doctor of Philosophy in Biomedical Sciences from Texas A&M University, where graduate studies were completed from 2010 to 2013, and a Master of Biotechnology along with a Graduate Level Certificate in Business from Texas A&M University from 2008 to 2010. Earlier education included a Bachelor of Pharmacy from the Institute of Chemical Technology, Mumbai University, completed in 2008. Onkar's professional experience also includes internships at Pfizer and Sangene Biotech Pvt Ltd.
This person is not in the org chart
This person is not in any teams
Emmecell
Emmetrope Ophthalmics LLC, (aka “Emmecell”) is a privately-held, clinical stage biotechnology company developing cell-based therapies. Emmecell’s platform technology leverages magnetic nanoparticles to effectively localize and integrate cell therapies to the appropriate target tissue. Our lead product EO2002 is a cell therapy for treatment for corneal edema, the most common indication for corneal transplantation. Cell Manufacturing and Production LLC (CellMP) was founded in 2018 and is a subsidiary of Emmecell providing GMP manufacturing services in Menlo Park, CA.